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Abstract
Beta-amyloid (Ab) peptides are considered to play a major role in the pathogenesis of Alzheimer’s disease (AD) and
molecules that can prevent pathways of Ab toxicity may be potential therapeutic agents for treatment of AD. We have
previously reported that NK-4, a cyanine photosensitizing dye, displays neurotrophic and antioxidant activities. In this study,
we report the effects of NK-4 on the toxicity of Ab and on cognitive function and Ab concentration in a transgenic mouse
model of AD (Tg2576). In vitro, NK-4 effectively protected neuronal cells from toxicity induced by Ab. In addition, it displayed
profound inhibitory activities on Ab fibril formation. In vivo, Tg2576 mice received an intraperitoneal injection at 100 or
500 mg/kg of NK-4 once a day, five times a week for 9 months. Administration of NK-4 to the mice attenuated impairment of
recognition memory, associative memory, and learning ability, as assessed by a novel object recognition test, a passive
avoidance test, and a water maze test, respectively. NK-4 decreased the brain Ab concentration while increasing the plasma
amyloid level in a dose-dependent manner. NK-4 also improved memory impairments of ICR mice induced by direct
intracerebroventricular administration of Ab. These lines of evidence suggest that NK-4 may affect multiple pathways of
amyloid pathogenesis and could be useful for treatment of AD.
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Introduction
Alzheimer’s disease (AD) is the most common cause of dementia
in elderly people and affects more than 25 million individuals
worldwide. The development of therapeutic strategies for AD is a
major unmet medical need. Inhibition of acetylcholinesterase
(AChE) is currently a primary therapeutic strategy for the mid to
late phase of AD because restitution of a close to normal
acetylcholine concentration in the synaptic cleft to enhance
cholinergic neurotransmission could ameliorate symptoms of
AD. However, the therapeutic effect of AChE inhibitors is only
symptomatic and short-term, and therefore new treatments are
needed as disease-modifying therapy for AD.
Elevation of the levels of b-amyloid (Ab), a ,4 kDa secreted
polypeptide, is thought to be involved in the pathogenesis of AD
because mutations in the Ab precursor protein (AbPP) or
presenilin genes that lead to increased production of Ab are
causative for familial AD [1-8]. Elevated levels of Ab are also well
correlated with cognitive decline in the early phase of dementia
[9]. This indicates that suppression of Ab in the brains of patients
in the early phase of dementia is a primary therapeutic target. The
majority of new treatments aim to inhibit Ab toxicity. These
include Ab immunotherapies that enhance clearance of accumu-
lating Ab in brain and secretase inhibitors that inhibit production
of Ab from AbPP. Inhibitors of Ab aggregation are also currently
under development, because the secondary structure determines
several important properties of Ab that may be relevant to the
pathogenesis of AD.
The Tg2576 mouse model of AD expresses a high level of the
Swedish mutation of AbPP under control of the hamster prion
protein promoter, which leads to elevated Ab production and
accumulation in brain [10,11]. The Tg2576 strain does not exhibit
aggressive neuronal degeneration, but the mice display age-
dependent cognitive dysfunction [10,12–14] and are therefore an
excellent tool for evaluation of Ab-targeted pharmacological
agents.
NK-4 is a divalent cationic pentamethine trinuclear cyanine dye
that contains three quinolinium rings, short N-alkyl side chains
(C2) and two iodine anions. NK-4 has a variety of biological
activities, including antimicrobial [15], macrophage-activating
[16], and anticancer properties, and is used as an immunomod-
ulator in treatment with antiviral and anticancer agents [17]. NK-
4 also has anti-inflammatory properties [18] and has been used to
treat allergy [19].
Recently, we found that NK-4 was a potent neurotrophic agent
for promotion of growth and differentiation of neuronal PC12
cells. The neuroprotective effects of NK-4 are mediated by
activation of PI3K-Akt and inactivation of SAPK/JNK indepen-
dently of the TrkA receptor at nanomolar concentrations [20].
NK-4 is also a potent scavenger of hydroxyl radicals (IC50:
7.6 mM), peroxy radicals (IC50: 5.2 mM), and superoxides (IC50:
89.3 mM), and these activities are greater than those of ascorbate
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injury in a rat model of middle cerebral artery occlusion [21] and
for motor discoordination and cerebellar atrophy in a genetic
animal model of cerebellar ataxia, without causing significant
adverse reactions [20].
In the present study, we investigated the effects of NK-4 on AD
in vitro and in vivo. We show that NK-4 is effective against Ab25–35-
induced cytotoxicity in PC12 cells, and that NK-4 directly inhibits
fibril formation of three forms of Ab peptide (Ab25–35,A b1–40 and
Ab1–42). In AbPP Tg mice, NK-4 significantly improved cognitive
dysfunction in association with a substantial decrease in the Ab-
immunoreactive tangles and Ab concentrations in the brain.
Moreover NK-4 reversed cognitive impairments induced by an




penylene] bis(1- ethylquinolinium iodide)) was synthesized at
Hayashibara Biochemical Laboratories, Inc. (Okayama, Japan).
A stock solution of 5 mg/ml NK-4 was prepared in DMSO and
stored at room temperature with protection from light. Just
before use, the stock solution was diluted with medium to give a
25 mg/ml solution. This working solution was used for experi-
ments with further dilution. Ab25–35,A b1–42 and Ab1–40 were
obtained from Anaspec (San Jose, CA). All other chemicals were
purchased from Sigma-Aldrich (St. Louis, MO), unless otherwise
indicated.
Cell Culture
The rat pheochromocytoma cell line PC12 (Human Science
Research Resources Bank, Osaka, Japan) was cultured in
Dulbecco’s Modified Eagle Medium (D-MEM; Nissui, Tokyo,
Japan) supplemented with heat-inactivated 10% (v/v) fetal bovine
serum and 5% (v/v) horse serum. For cell growth and neurite-
outgrowth assays, PC12 cells were harvested using 0.1% (w/v)
trypsin containing 0.03% (w/v) EDTA and seeded at a density of
5,000 cells/100 ml in 96-well plates pre-coated with collagen type
IV. After a 24 hr pre-culture, PC12 cells were exposed to Ab25–35
(50 mM) in the presence or absence of NK-4 for 72 hr. Ab25–35
peptide were dissolved in DMSO (2 mM) and kept at 280uC.
Just before use, the solution was diluted in distilled water
(200 mM) and incubated at 37uC for 16 hr. This procedure, called
‘‘aging’’, promotes formation of stable oligomeric aggregates and
enhances the cytotoxicity of the preparation. Cell survival was
determined using alamarBlue dye (Trek Diagnostic Systems,
Cleveland, OH) [22].
Thioflavin T (ThT) Fibril Formation Assay
The Ab fibril formation assay was performed as described
previously [23]. Stock solutions of Ab1–40,A b1–42 and Ab25–35
were prepared in DMSO (1 mg/ml) and stored at 280uC. Just
before the experiment, the stock solution was diluted with 10 mM
phosphate buffer containing 100 mM KCl (pH 7.4). The diluted
Ab solutions were incubated at 37uC in the presence or absence of
indicated concentrations of NK-4 for 72 hr. Fifty ml of the
incubated samples containing 100 mMA b peptides were added to
450 mlo f1 0mM ThT in 10 mM phosphate and 100 mM KCl
(pH 7.4). Fluorescence intensity was measured with excitation at
435 nm and emission at 485 nm using a Hitachi 650-60
fluorescence spectrophotometer. The results are expressed as the
mean 6 SD of three samples.
Electron Microscopy
Amyloid fibril formation was verified by electron microscopy
(EM) images of negatively stained samples. A 20-ml sample of Ab1–
40 or Ab1–42 solution incubated with or without NK-4 was placed
on a polyvinyl butyral-coated copper mesh grid (Oukenshoji,
Tokyo, Japan). The sample was allowed to stand for 30–60 s and
excess solution was washed away. Subsequently, samples were
negatively stained with 2% (w/v) uranyl acetate (Kowayakuhin,
Saitama, Japan) and allowed to dry. After staining, the samples
were viewed with a JEM-100CX/II electron microscope (Joel
Ltd., Tokyo, Japan) at 80 kV.
Animals
All animal protocols were approved by the Institutional Animal
Care and Use Committee of Hayashibara Biochemical Labora-
tories (permit number F-1002) and were conducted in accordance
with the guidelines for the Care and Use of Laboratory Animals at
Hayashibara Biochemical Laboratories. Female AbPP transgenic
mice (Tg2576, 129S6/SvEvTac background) expressing a double
mutation of human AbPP [24], and age- and sex- matched non-
transgenic mice were obtained from Taconic (Germantown, NY).
The mice were housed individually with supplied nesting
materials, and food and water were provided ad libitum. NK-4
solution was injected intraperitoneally at a dose of 100 or 500 mg/
kg once a day, five times a week for 9 months, beginning at 3
months of age. Control mice received 200 ml of saline. During the
behavioral test periods, NK-4 or saline was administered 2,3h r
before the start of each test. Male ICR mice (5 weeks of age,
weighing 25–30 g) were purchased from Charles River Japan
(Kanagawa, Japan).
Ab25-35-Induced Cognitive Impairments in ICR Mice
Cognitive impairment was induced by a direct intoracerebro-
ventricular (icv) administration of aggregated Ab25–35 peptide in
mice according to the method described by Maurice et al. [25].
Ab25–35 was dissolved in saline at the concentration of 1.0 mM
and incubated at 37 uC for 4 days, called ‘‘aging’’ process. On
day0, aged Ab25–35 solution (9 nmole/6 ml/mouse) was injected by
a micro-stainless needle (inner diameter: 0.13 mm) into the left
lateral ventricle of ICR mice using following coordinates from
Bregma: 0.5 mm posterior, 1.0 mm lateral, and 2.0 mm ventral.
Sham operated mice received 6 ml of saline instead of Ab25–35
solution. From the next day of Ab-icv injection (day1), NK-4
solution was injected intraperitoneally at a dose of 50 or 500 mg/
kg/day for twelve consecutive days. Control mice received 200 ml
of saline. Mice were tested for object recognition and passive
avoidance according to the methods described below during the
day6–8 and day9–12, respectively.
Novel Object Recognition Test
The task was carried out according to a previous report [26]
with minor modification. The apparatus used in this study was an
opaque plastic box (40650630 cm) with a clear acrylic cover plate
on the top, the floor of which was covered with wood tips. The
novel object recognition task comprised the following three
sessions. First, in a habituation session, mice were individually
placed in the box for 10 min of exploration in the absence of
objects. Second, a training session was performed 24 hr after the
habituation session. Two objects (A and B) were placed in the back
corner of the box, 10 cm from the sidewall. Mice were individually
placed in the middle front of the box and the time spent in
exploring the two objects was recorded. Exploration behavior of
the mice was defined as directing the nose toward the object at a
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performed 24 hr after the training session. One of the familiar
objects (B) used in the training session was replaced by a novel
object C, and objects A and C were placed as in the previous
session. Mice were then individually placed in the box and allowed
to explore freely for 10 min, with recording of the time spent in
exploring each of the two objects. The exploratory preference was
expressed as a ratio of the time spent exploring the novel object
(TC) over that spent on the two objects (TA+TC): exploratory
preference (%) = TC/(TA+TC) 6100.
Water Maze Test
A circular pool (diameter =130 cm, Nishinihonkikou,
Okayama, Japan) was filled with water to a height of 15 cm.
White ink was used to render the water opaque. The water
temperature was maintained at 2361uC throughout the trials. To
enhance the positional recognition of mice, four different
geometric patterns were placed at inner rim of each quadrant of
the pool as well as each wall of the room. On the first day (day0),
the platform (diameter =9 cm) was placed at the midpoint of the
pool, 0.5 cm above the water surface. Each mouse was placed on
the platform and allowed to move away from the platform and
swim in the pool for 15 sec, then gently guided to the original
platform. The next day (day1), the platform was placed at the
midpoint of one quadrant, submerged 0.5 cm below the water
surface. The position of the platform was unchanged throughout
the test trials. Two trials each day with an inter-trial interval of
1 min were conducted for 4 consecutive days (day1 to day4). In
each trial, the mice were placed in the pool at one starting
position, with their back turned to the midpoint of the pool. They
were allowed to swim freely or until they found the hidden
platform and came up for air while on the platform. The time
required to escape onto the hidden platform was recorded as
escape latency. If a mouse did not reach the platform within
120 sec, it was gently guided to the platform, where it remained
for 10 sec. Starting locations were changed every trial. The results
of 2 trials were averaged and used in data analysis.
Passive Avoidance Test
A passive avoidance test was conducted using the apparatus
consisted of two separate chambers (30630620 cm height). One
of the chambers was illuminated and the other was dark. Each
chamber was separated by a small guillotine door (3.565 cm) and
grids were attached on the floor in the dark chamber. This test
comprised the following 3 sessions. First, in a pre-training session
(day1 and day2), mice were individually placed in the illuminated
chamber for 1 min and then in the dark chamber for 2 min.
Second, in the test session (day3), mice were individually placed in
the illuminated chamber. Immediately after the mice entered the
dark chamber, the door was locked and an electrical stimulation of
0.36 mA was applied for 2 sec. The time spent in the illuminated
chamber was measured. Third, in the retention session (day4),
which was performed 24 hr later, mice were placed back in the
illuminated chamber and the time spent in this chamber before
entering the dark chamber was measured. The latency in the
retention session was expressed graphically and used in data
analysis.
Measurement of Ab Species from Plasma and Brain
Homogenates by ELISA
After mice were deeply anesthetized with pentobarbital (50 mg/
kg), blood samples were withdrawn from the postcaval vein using
heparinized syringe and the plasma was prepared and used fresh
or was stored at 280uC until use. Cerebrospinal fluid (CSF) was
collected from the dura mater over the cistern magna and brains
were isolated. Hemi-brains were weighed and homogenized with
a teflon-glass homogenizer in 20 mM Tris-buffered saline (TBS;
137 mM NaCl, protease inhibitor cocktail, pH7.6), and
centrifuged at 100,0006gf o r1h ra t4 uC. Pellets were
resuspended in TBS containing 2% SDS. After centrifugation
at 100,0006gf o r1h ra t4 uC, the supernatant was obtained as
t h es o l u b l ef r a c t i o no fA b, and the pellet was extracted with 70%
(w/v) formic acid, followed by centrifugation at 100,0006gf o r1
hr at 4uC. The supernatant was neutralized by 20-fold dilution
with 1 M Tris base [27] and used as the insoluble Ab fraction.
Samples were diluted with the diluents provided in the human
(h)Ab1–40 and hAb1–42 ELISA kits (Wako, Osaka, Japan). hAb1–
40 and hAb1–42 in individual samples were quantified in
accordance with the manufacturer’s instructions and are
expressed as picomoles/mL of plasma or picomoles/mg wet
weight of brain (mean 6 SEM).
Histology
Hemi-brains were fixed with 10% buffered formalin for 24 hr
and embedded in paraffin blocks, and then coronal sections of
cerebral cortex with 5 mm thickness were stained with Congo-Red
for counting amyloid plaques. For Ab immunohistochemistry,
paraffin sections were dewaxed, rehydrated, and then blocked with
PBS containing 0.2% Triton X-100 and 5% BSA. Sections were
then incubated with rabbit anti-Ab-peptide polyclonal antibody
(#71-5800, 1:50) (Invitrogen, Camarillo, CA) at 4uC overnight.
After several washes in PBS, sections were incubated with HRPO-
conjugated secondary antibody (DAKO, anti-rabbit Igs, 1:2000)
and then Ab-immunoreactive tangles were visualized by diami-
nobenzidine.
Statistical Analysis
All values are expressed as means 6 SD or SEM. A Student t
test was used for comparison between 2 groups. One-way
ANOVA with a Tukey-Kramer test was used to determine the
significance of differences in multiple comparisons. In water maze,
repeated measures two-way ANOVA followed by a post hoc
Sheffe’s F test was applied. Pearson correlation analysis was used
to examine the correlation between Ab levels in plasma and brain
in each mouse. Differences with a probability value of P,0.05
were considered to be significant.
Results
Effects of NK-4 against Ab-Induced Neurotoxicity in PC12
Cells
We first determined whether NK-4 was effective against Ab-
induced neurotoxicity in vitro using PC12 cells. These cells (either
undifferentiated or differentiated with nerve growth factor) are
reported to be the most sensitive to Ab protein or the Ab25–35
fragment [28]. The cytotoxicity of Ab25–35 peptide is stronger than
that of Ab1–40 in both PC12 cells and hippocampal neurons,
which defined residues 25–35 as the active region of the Ab
protein [28]. The cytotoxicity of Ab25–35 developed rapidly and
was detected within 2 hr after application, and then reached a
plateau after 72 hr of incubation (data not shown). The viability of
PC12 cells treated with 50 mMA b25–35 for 72 hr was about 45%
compared with controls without Ab25–35 (Fig. 1). NK-4 dose-
dependently attenuated the effect of Ab25–35 and the results were
significant at doses over 10 nM. NK-4 substantially reversed the
cellular damage at 250 nM.
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To examine the potential mechanisms of NK-4-mediated
protection of neuronal cells from amyloid toxicity, we evaluated
the effect of NK-4 on aggregation or fibrillization of three forms of
Ab peptide. Solution of Ab1–40 or Ab1–42 (100 mM each) was
incubated at 37uC for 3 days in the absence or presence of NK-4
at the indicated concentrations (Fig. 2). After the incubation,
visible sedimentary aggregates were observed in the Ab controls,
while the addition of NK-4 had reduced visible aggregates. To
examine the effect of NK-4 further, EM was used to monitor Ab
fibril formation. In EM, Ab1–40 alone formed long and
unbranched fibrils (Fig. 2a). In contrast, Ab1–40 incubated with
NK-4 (10 mM) had shorter and fewer filaments with soluble
assemblies (Fig. 2b). Similarly, Ab1–42 formed dense fibrils (Fig. 2c)
and they were remarkably weakened by the co-incubation with
NK-4 (Fig. 2d). ThT fluorescence is enhanced upon binding to Ab
fibrils, proportionally to the amount of fibrils in solution [23]. So,
we used ThT to evaluate the effect of NK-4 on the Ab fibril
formation quantitatively. All three forms of Ab solutions showed
enhanced emission at 482 nm, which is characteristic for ThT
bound to amyloid fibrils. NK-4 inhibited all these ThT
fluorescence dose-dependently (Fig. 2e). The inhibitory effect of
NK-4 was most prominent on Ab1–40, then followed by Ab1–42
and Ab25–35. An equimolar concentration of NK-4 almost totally
inhibited the ThT fluorescence in all three forms of Ab. These
results suggest that NK-4 is an effective inhibitor of Ab fibril
formation in vitro.
Effects of NK-4 on Recognition Memory in the Novel
Object Recognition Test
Given the beneficial effects of NK-4 on multiple aspects of
amyloid pathology in vitro, we next examined whether NK-4 had
an effect on the cognitive deficit induced by Ab in an AbPP
transgenic mouse model of AD. Tg2576 mice expressing the
Swedish mutation of AbPP were administered with 100 or
500 mg/kg NK-4 once a day, 5 times a week for 9 months,
beginning at 3 months of age. Wild type and Tg2576 mice were
tested for object recognition memory 24 hr after training to test
long-term memory at ages 3, 6 and 12 months. During the training
session, there were no significant differences in exploratory
preference between the two objects or in the total exploratory
time among the groups (data not shown). At 3 months of age, we
could not detect significant differences in recognition memory
among all groups tested (data not shown). In the retention session,
Tg2576 mice at ages 6 and 12 months showed significantly
decreased object recognition memory compared with that in the
wild type mice at the respective ages (Fig. 3). Tg2576 mice treated
with a low dose of NK-4 (100 mg/kg) tended to spend a longer
Figure 1. Cytoprotective effects of NK-4 on Ab25–35-induced
cytotoxicity in PC12 cells. PC12 cells were treated with 50 mMA b25–
35 for 72 hr in the absence (open bar) or presence of the indicated
concentrations of NK-4 (closed bars). Control cells were incubated
under the same conditions, but without Ab25–35. Cell viability was
assessed by alamarBlue assay. Results are shown as means 6 SD (n=3).
**P,0.01 vs. no NK-4.
doi:10.1371/journal.pone.0030007.g001
Figure 2. Effects of NK-4 on Ab fibril formation. 100 mMo fA b1–40
(a, b) or Ab1–42 (c, d) was incubated for 72 hr alone (a, c) or with NK-4
(10 mM) (b, d). Bar represents 200 nm. The experiment was performed
three times with similar results. (e) Thioflavin T assay of Ab fibril
formation. Three forms of Ab peptide (Ab1–40,A b1–42 and Ab25–35) were
incubated for 72 hr with the indicated concentration of NK-4. Values are
means 6 SD (n=3). **P,0.01 vs. control (without NK-4).
doi:10.1371/journal.pone.0030007.g002
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at both 6 and 12 months of age (treated for 3 and 9 months), but
the differences were not significant. In contrast, Tg2576 mice
treated with a high dose of NK-4 (500 mg/kg) spent a significantly
longer time exploring the novel object than did the saline-treated
mice at both 6 and 12 months of age, and the exploratory
preference was comparable to that of wild type controls at age 12
months (after 9 months treatment). This suggests that NK-4
administration for a longer period might be more effective for
improvement of object recognition memory.
Effects of NK-4 on Learning Ability in the Water Maze
Test
We also evaluated learning ability of mice in a water maze test
at ages 6 and 12 months (Fig. 4). Group differences in the escape
latency of the training trial session were analyzed using two-way
ANOVA with repeated measures. There were significant differ-
ences in escape latency between genotype (wild type controls vs.
saline-treated Tg2576 mice) at 6 months of age [Genotype6Time
F(1,54) =40.531, P,0.001], and at 12 months of age [Genotype
6 Time F(1,48) =7.269, P,0.05]. For saline-treated Tg2576
group, the latency to reach the platform did not shorten during the
whole test period at 12 months of age. There was a significant
Genotype 6Time interaction [F(3,48) =5.0732, P,0.01] at this
stage, suggesting that the learning ability of saline-treated Tg2576
mice became impaired with age.
We found significant differences in escape latency between
treatments (NK-4 vs. saline) at 6 months of age [Group 6Time
F(2,81) =10.404, P,0.001], and at 12 months of age [Group 6
Time F(2,75) =5.671, P,0.01]. The interaction of the grouping
Figure 3. Effects of NK-4 on cognitive function of Tg2576 mice in a novel object recognition test. A low (100 mg/kg) or high (500 mg/kg)
dose of NK-4 was administered intraperitoneally to female Tg2576 mice from 3 to 12 months of age. Mice were tested for object recognition at 6 and
12 months of age. Values are means 6 SEM (n=10). **P,0.01 vs. saline-treated Tg2576 group. Wild: non-transgenic female 129S6 mice. Tg2576
(saline): saline-treated Tg2576 mice. Tg2576 (NK-4l): low-dose NK-4-treated Tg2576 mice. Tg2576 (NK-4h); high-dose NK-4-treated Tg2576 mice.
doi:10.1371/journal.pone.0030007.g003
Figure 4. Effect of NK-4 on learning ability of Tg2576 mice in a water maze test. Mice were tested for learning ability at 6 and 12 months of
age. The mean latency represents the time spent finding a hidden platform placed in a fixed location in the pool. Two trials per day were conducted
for 4 consecutive days. Data are expressed as means 6 SEM of the averaged time on each day (n=10). *P,0.05, **P,0.01 vs. saline-treated Tg2576
group.
doi:10.1371/journal.pone.0030007.g004
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of age [F(6,81) =2.672, P,0.05]. Saline-treated Tg2576 group
consistently exhibited a longer latency than NK-4-treated Tg2576
groups. Both low (100 mg/kg) and high (500 mg/kg) doses of NK-4
improved learning ability of Tg2576 mice with significant
differences compared with saline-treated controls (P,0.01 at 6
months of age, P,0.05 at 12 months of age), but the effects of NK-
4 on escape latency did not differ significantly between these two
doses. The swimming ability did not differ significantly among
Tg2576 groups (data not shown).
Effects of NK-4 on Passive Avoidance Memory
Recognition memory of NK-4-treated mice at ages 3 and 9
months was evaluated in a passive avoidance test. Similar to the
novel object recognition test, no significant difference was detected
in latencies for entering the dark chamber of a passive avoidance
apparatus during the retention session among all groups tested at 3
months of age (data not shown). However at 9 months, there was a
significant difference in latencies between wild type control and
saline-treated Tg2576 mice (p,0.01). Both low (100 mg/kg) and
high (500 mg/kg) doses of NK-4 reversed the decrease in passive
avoidance latency of Tg2576 mice, and the differences were
significant compared with saline-treated controls (both p,0.01,
Fig. 5). There was no difference in latencies for entering the dark
chamber between wild type and Tg2576 mice, or among the
treatment groups after placement in the light chamber for the first
time during the training session (in the absence of shock). All
animals took an average of 70 s to move to explore the dark
chamber, indicating no baseline differences in anxiety in the
treatment groups in this behavioral test. We also found no
difference in shock sensitivity among wild type and saline- and
NK-4-treated Tg2576 mice.
Effect of NK-4 on Ab Levels in Tg 2576 Mice
We next evaluated whether NK-4 displayed any significant
effect on Ab levels in plasma, CSF and brains from Tg2576 mice.
Since NK-4 might directly interact with Ab peptides, we examined
whether it interferes the Ab ELISA. Although the presence of NK-
4 slightly enhanced optical density values in Ab ELISA systems,
the range of increase was less than 5% when the NK-4:Ab molar
ratio was 0.1,100 (Fig. 6a, b). This indicated that NK-4 hardly
affects both Ab1–40 and Ab1–42 ELISA systems.
Dose-dependent increases in Abx-40 and Abx-42 were observed
in plasma from NK-4 treated mice (Fig. 6c, d). In contrast, CSF
Abx-40 and Abx-42 levels were not significantly changed by NK-4
treatment, although the CSF concentrations of Abx-40 and Abx-42
in NK-4 treated mice tended to be lower than those in saline-
treated controls (data not shown). Brain levels of Ab were
estimated separately in soluble and insoluble fractions. Both
soluble and insoluble Abx-40 levels were significantly decreased by
NK-4 treatment (Fig. 7a, c). Similarly, levels of Abx-42 were lower
in NK-4 treated mice, with a significant decrease in insoluble Abx-
42 (Fig. 7b, d). The levels of Abx-40 and Abx-42 in brain were
inversely correlated with those in plasma (r=20.69, P,0.01
(n=27), and r=20.42, P,0.05 (n=27), respectively) (Fig. 7e, f).
We next surveyed brain Ab deposition of Tg2576 mice by
Congo Red (CR) staining and Ab immunohistochemistry (Fig. 8).
Wild type mice did not show any sign of amyloid deposition in
their brain at 12 month of age (Fig. 8a). Tg2576 mice at the same
age developed distinguishable, but very few amount of plaques in
their cortex region. The number of CR-positive plaques in the
cerebral cortex region was not significantly changed among saline-
treated group and NK-4-treated groups (Fig. 8a). On the contrary,
Ab-immunoreactive small tangles were abundantly seen in the
cortex of saline-treated Tg2576 mice (Fig. 8b), and they were
obviously reduced by the high dose NK-4 treatment both in size
and in quantity (Fig. 8c).
Effects of NK-4 on Ab25-35-Induced Cognitive
Impairment in ICR Mice
To confirm whether the effect of NK-4 was directly attributable
to mitigation of Ab pathology, we employed an Ab-induced
amnesia model, in which ICR mice received intracerebrovan-
tricular (icv) administration of aged Ab25–35 peptide to provoke
memory deficits [25]. Long-term recognition memory was
evaluated by the novel object recognition test and the passive
avoidance test starting at 6 days and 9 days after Ab25–35-icv
injection, respectively. In both behavioral assays, daily NK-4-
treatment dose-dependently, and significantly improved the
memory deficits induced by Ab (Fig. 9a, b). These results, in
combination with the results from Tg2576 mice, strongly
suggested that NK-4 treatment improved Ab-mediated memory
impairments.
Discussion
NK-4 is a N-heterocyclic cationic dye derivative that contains
three quinolinium rings and two iodine anions. Although NK-4
shows a variety of biochemical and biological activities [15–21],
structure-activity relationships or molecular mechanisms of them
remain largely unknown. Extended p-electron conjugated system of
NK-4 would considerably contribute to antioxidative effects by
trapping free radicals similar to another cyanine dye platonin [29].
The extended conjugated system also confers this molecule a planar
structure by which NK-4 seems to bind at the interface of the b-
sheet domains of the proteins and act as a ‘‘b-sheet breaker’’ [30].
On the other hand, it is reported that the side chain length affects
Figure 5. Effect of NK-4 on cognitive function of Tg2576 mice
in a passive avoidance test. Mice were tested for learning at 9
months of age. The latency in the retention session performed 24 hr
after the training session is shown. Values are means 6 SEM (n=10).
**P,0.01 vs. saline-treated Tg2576 group.
doi:10.1371/journal.pone.0030007.g005
Effects of a Cyanine Dye for Amyloid Pathology
PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e30007water solubility or affinity to the lipid membrane in this kind of dye
compounds [31]; therefore, the specific activity of NK-4 might
change in accordance with the length of N-alkyl side chains.
Application of neurotrophic small molecules that modulate
neuronal survival and synaptic function is a promising therapeutic
approach for AD, while modulation of the amyloid pathology is a
key strategy for slowing or halting the disease progression. In this
study, we showed that NK-4 protected neuronal cells from Ab25–
35-induced toxicity (Fig. 1). Attenuation of Ab cytotoxicity by NK-
4 might be caused by direct action on Ab to prevent its
aggregation into more toxic forms, or via activation of intracellular
survival signaling pathways and inactivation of death pathways in
neuronal cells [20], or both. The effect of NK-4 on Ab fibril
formation was significant, but the IC50 value for Ab aggregation
was approximately 10 mM for Ab1–40 and Ab1–42, and 30 mM for
Ab25–35 (Fig. 2e). In contrast, a much lower concentration (nM
level) of NK-4 attenuated the neurotoxicity induced by 50 mM
Ab25–35 in PC12 cells (Fig. 1). These results suggest that NK-4
attenuates Ab-induced toxicity via activation of intracellular
survival signaling pathways including Akt activation [20], rather
than direct inhibition of Ab aggregation, since the concentration of
NK-4 required inhibiting Ab aggregation was substantially high.
However, the effect of NK-4 on Ab aggregation was greater than
those of non steroidal anti-inflammatory drugs (NSAIDs) such as
ibuprofen, naproxen, ketoprofen, and indomethacin [32,33],
which require at least a threefold higher concentration to inhibit
Ab aggregation. Therefore, the anti-fibrillization effect of NK-4
might play some role in attenuating Ab toxicity in vivo.
Chronic administration of NK-4 to Tg2576 mice significantly
attenuated cognitive decline as assessed in a set of behavioral tests
(Fig. 3,4,5), and also decreased the levels of Ab in brain (Fig. 7) and
augmented those in plasma (Fig. 6). These results imply that the
NK-4-induced behavioral improvement was attributable to
decreased Ab in brain, and that Ab may be cleared across the
Figure 6. Effect of NK-4 on the plasma Ab concentrations in Tg2576 mice. NK-4 did not interfere the optical density of both hAb1–40 (a) and
hAb1–42 (b) ELISA systems, which using the antibody combinations of BAN50/BA27 and BAN50/BC05, respectively. Since these ELISA systems cannot
distinguish N-terminal heterogeneity of Ab peptides derived from biological samples, we represented hAb species as hAbx-40 and hAbx-42,
respectively. Plasma from mice aged 12 months was used for measurements of hAbx-40 (c) and hAbx-42 (d). Values are the mean 6 SEM for saline-
treated Tg2576 mice (control group, n=10), a low dose NK-4 (100 mg/kg)-treated group (n=9), and a high dose NK-4 (500 mg/kg)-treated group
(n=8). **P,0.01 vs. saline-treated Tg2576 group.
doi:10.1371/journal.pone.0030007.g006
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Ab was found after peripheral administration of an anti-Ab
antibody in an AD mouse model [34]. Although there is still no
consensus as to the mechanism by which anti-Ab antibodies alter
amyloid deposition, in vivo binding properties of the antibodies
would affect plasma Ab levels by altering the half-life of Ab [34].
In a similar fashion, a direct NK-4 binding to Ab in Tg2576 mice
may be one possible explanation of augmented plasma Ab levels
by chronic peripheral administration of NK-4. On the other hand,
plasma might serve as a sink that enhances clearance of Ab from
the brain based on a peripheral sink hypothesis [35,36], because
Ab clearance mainly occurred in plasma in Tg2576 mice [34]. It
might be also possible that direct NK-4 binding to Ab creates a
sink that enhances clearance of Ab deposition from brain. In either
case, further study is required to address these issues.
It seems unlikely that the impaired performance of Tg2576 mice
in learning and memory tests is due to changes in motivation or
sensorimotor function, since the motivation for each behavioral
test is different and different skills are required for a good
performance in each test. There were no differences in locomotor
activity, total time spent exploring objects in the novel object test
between wild type and Tg2576 mice. Recognition memory in the
novel object test and associative learning in the passive avoidance
test are dependent on the hippocampus and/or perirhinal cortex
Figure 7. Effect of NK-4 on brain soluble or insoluble Abx-40 and Abx-42 in Tg2576 mice. Brains from mice aged 12 months were
homogenized and separated into soluble (c, d) and insoluble (a, b) fractions of Ab, and assayed for hAbx-40 (a, c) and hAbx-42 (b, d), respectively. FA:
SDS insoluble and formic acid soluble fractions of Ab. SDS: SDS soluble fractions of Ab. Correlations are shown between the plasma and brain levels of
hAbx-40 (e) and hAbx-42 (f) in Tg2576 mice. Data are the mean 6 SEM of hAbx-40 or hAbx-42 in each mouse in saline-treated Tg2576 controls (n=10), a
low dose NK-4 (100 mg/kg)-treated group (n=9), and a high dose NK-4 (500 mg/kg)-treated group (n=8). *P,0.05, **P,0.01 vs. saline-treated Tg2576
group.
doi:10.1371/journal.pone.0030007.g007
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PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e30007Figure 8. Ab deposition in brains of Tg2576 mice at 12 months of age. Coronal brain sections (cortex region) were stained by Congo Red (a)
or anti-Ab polyclonal antibody (b, c). The number of CR-positive plaques on the section was counted in cortex region (a). Typical images of Ab-
immunoreactive tangles of saline-treated Tg2576 mouse (b) and high-dose NK-4(500 mg/kg)-treated Tg2576 mouse (c). Bar represents 50 mm.
doi:10.1371/journal.pone.0030007.g008
Figure 9. Effects of NK-4 on Ab25–35-induced cognitive impairments in ICR Mice. Cognitive impairment was induced in ICR mice by icv
injection of Ab25–35 solution as described in Material and Method. A low (50 mg/kg) or high (500 mg/kg) dose of NK-4 was administered
intraperitoneally to mice twelve consecutive days starting from the next day of Ab injection (day1). Mice were tested for object recognition (a),
followed by passive avoidance (b). Values are means 6 SEM (n=10). Sham: sham-operated group, saline: saline-treated Ab25–35–icv group, NK-4l: low-
dose NK-4-treated Ab25–35–icv group, NK-4h; high-dose NK-4-treated Ab25–35–icv group. *P,0.05, **P,0.01 vs. saline-treated group.
doi:10.1371/journal.pone.0030007.g009
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campus and/or perirhinal cortex-dependent memory started as
early as 6 months of age and continued to 12 months of age in
Tg2576 mice in our experiment. Contrary to this, histological
investigation of Ab deposits in Tg2576 mice showed no substantial
differences in quantity of CR-positive plaques among the saline-
treated group and NK-4-treated groups at 12 month of age
(Fig. 8a). On the other hand, Ab-immunoreactive tangles were
abundant in the cortex of saline-treated Tg2576 mice and they
were clearly decreased by high dose NK-4 treatment in good
agreement with the results of Ab ELISAs (Fig. 7, Fig. 8b, c), and it
might also reflect the cognitive function (Fig.3, 4). The difference
in plaque stainability between CR and anti-Ab would be due to
the sensitivity to immature tangles, and therefore, CR staining
might not reflect the total amount of Ab deposition in brain.
The Tg2576 mouse is the most thoroughly characterized AD
mouse model and is considered to reflect the human amyloid
pathology most closely among mouse models [11]. Although many
studies using mice on a B6/SJL background (hereafter; Tg2576/
B6), we used here the newly developed 129S6/SvEvTac strain
(hereafter; Tg2576/129) established by Taconic, because this
strain does not carry a retinal degeneration mutation [24]. The
129 strains are reported not appropriate for water maze tasks
according to previous studies [40–43], however, the wild type mice
of 129S6/SvEvTac strain performed well in the acquisition
learning of water maze test [44]. Regarding the timing of cognitive
decline, our results showed that the Tg2576/129 did not exhibit
cognitive decline at the age of 3 months (data not shown), but
became apparent at 6 months, which continued to 12 months
(Fig. 3,4,5). Reportedly, Tg2576/B6 showed no detectable
cognitive impairment at 3–4 months, but became obvious at 5–6
months of age [14,45–47]. Thus, genetic backgrounds appear not
to be affected in the timing of cognitive decline.
The water maze protocol we employed in this study is a variant
of Morris water maze navigation task. Although the original
protocol was designed for evaluating hippocampus-dependent
spatial reference learning and memory [48], our modified protocol
is not considered as the one for spatial cognition since we used
extra intra-maze landmarks and did not run a probe trial. We
placed proximal landmarks on the inner rim of the pool in
addition to each wall of the room (distal landmarks) aiming to
enhance positional recognition of mice, however, it is suggested
that the processing of information related to distal landmarks
(room cues) or proximal landmarks (intra-maze cues) are mediated
by different neural systems [49,50]. The hippocampus circuitry
contributes to a spatial strategy, which involves flexible use of
spatial/distal cues, whereas a cue strategic processing of proximal
landmarks is dependent upon striatal circuitry [50]. Thus, what we
evaluated using the extra proximal landmark condition would not
be spatial reference learning, but non-spatial or mixture of both.
On another note, the lack of probe trial made it difficult to confirm
the memory retention. As a result of these modified experimental
design, we could not determine whether the learning strategy of
the mice was spatial or not. One thing for certain is, however, that
NK-4 modulated the learning ability of Tg2576/129 mice in the
water maze task (Fig.4). The learning ability of Tg2576/129 mice
was impaired with age, and a long-term NK-4 treatment
significantly improved it. Results of two other behavioral tests
(Fig.3, Fig.5) support this notion.
In relation to the learning ability of the mice on 129 background,
it has been known that all 129 mouse substrains have disrupted-in-
schizophrenia 1 (DISC1) deletion mutation [51]. Because DISC1 is
reported to play a critical role in development and migration of
hippocampal neurons [52], cognitive deficits observed in 129 strains
maylinkedtolackofDISC1protein.Inthis regard,preferableeffect
of NK-4 on cognitive improvements of Tg2756/129 mice may be
attributable to restoring the dysfunctional DISC1-mediated path-
way. To address this question, we examined the effect of NK-4 on
Ab-dependent amnesic mice model [25]. As a result, NK-4
treatment dose-dependently and significantly attenuated memory
dysfunction induced by direct injection of Ab25–35 peptide into the
lateral ventricle of ICR mice (Fig. 9). Therefore, the modification of
DISC1-mediated pathway by NK-4 seems not mainly involved in
this case.SinceNK-4 activated PI3K-Aktpathway independently of
the TrkA receptor in vitro [20], activated Akt (p-Akt) may be an
important mediator of the beneficial effects on learning and
memory. The p-Akt is required for PI3K-mediated synaptic
plasticity and memory consolidation by promoting neuronal cell
survival and protein synthesis via phosphorylation of CREB, a
downstream regulator involved in hippocampus-dependent long-
term and spatial memory formation [53]. Therefore, induction of
Akt phosphorylation might play critical roles in NK-4-mediated
memory improvement in Tg2576/129 mice.
Oxidative mechanisms are also thought to be involved in the
cell loss and other neuropathology associated with AD [54,55]. In
AD pathogenesis, reactive oxygen species (ROS) impair mito-
chondrial redox activity and increases further ROS generation
[29,56,57]. Ab induces production of ROS and leads to apoptotic
neuronal cell death that can be inhibited by antioxidants [57–59].
Pathologic and biochemical studies suggest that ROS induced by
fibrillar Ab have neurotoxic effects [60,61]. As mentioned before,
NK-4 is a potent scavenger of ROS [21] and an inhibitor of Ab
aggregation (Fig. 2). Those activities might contribute to
attenuation of Ab toxicity in AD.
As to the safety profile, NK-4 was well tolerated in a mouse
acute oral toxicity study at up to 2 g/kg [21], based on mortality,
clinical observations, body weight, hematology, blood chemistry,
organ weights, and histological examinations of a full tissue list.
Additionally, NK-4 was not mutagenic in the standard Ames test
due to bacterial-specific metabolism (data not shown). Further-
more, there were no specific adverse events in mice those received
intraperitoneal injections of NK-4 at the dose of up to 500 mg/kg/
day, 5 days a week, for 9 months (this study). These observations
suggest that NK-4 is a safe compound that will not cause serious
adverse reactions. Following an intraperitoneal administration at
500 mg/kg, NK-4 penetrated the brain and nM levels were
detected using high-performance liquid chromatography [20].
Thus, the nM range used in the in vitro investigations in this study
corresponds to the calculated brain concentration in Tg2576/129
mice receiving NK-4.
In summary, the results of this study show that chronic
treatment with NK-4 from an early stage of cognitive dysfunction
significantly ameliorated learning impairments in Tg2576/129
AbPP mouse. The NK-4-induced behavioral improvement might
be attributable to decreased Ab accumulation in brain, and the
inhibitory effects on Ab aggregation, neurotrophin-like property,
as well as radical-scavenging effect of NK-4. Its multiple functions
might work in concert to attenuate AD pathology.
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